Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prediabetes Market

Prediabetes Market Trends

Report ID: GMI8874
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Prediabetes Market Trends

There is a growing emphasis on preventive healthcare globally, stimulated by the recognition of the significant burden that chronic diseases such as type 2 diabetes impose on healthcare systems and society as a whole.
Prediabetes represents a critical stage where interventions can be implemented to prevent or delay the onset of type 2 diabetes and its associated complications. This focus on preventive healthcare encourages investment in prediabetes screening, diagnosis, and management strategies, propelling the growth in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prediabetes industry size recorded USD 198.4 million in 2023 and will grow at a 6.9% CAGR between 2024 and 2032 owing to rise in obesity rates and sedentary lifestyles, emphasis on preventive healthcare measures and investments in screening programs.

The biguanides segment in the prediabetes industry will register USD 254.6 million by 2032, attributed to the effectiveness and widespread use of biguanides, such as metformin, as a first-line treatment for prediabetes.

North America prediabetes industry captured 40.7% revenue share in 2023, driven by high prevalence of prediabetes in the region, rising obesity rates, and sedentary lifestyles.

Prominent prediabetes firms are Abbott Laboratories, AstraZeneca PLC, CH Boehringer Sohn AG & Co KG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.